Key Takeaways
- Steady FY23, with a trade generics breakout: Consolidated revenue grew 10% YoY, but trade generics surged 49% YoY, powered by a direct-to-stockist IT-enabled distribution model that bypasses large intermediaries.
- Injectable facility is the next growth engine: Mechanical completion is targeted for end of Q2 FY24, with first commercial batches within FY24 and a major revenue contribution expected from FY25 onward.
- Exports are a back-ended bet on ROW markets: Revenue declined 26% YoY in Q4, but management is bullish on the long-term CMO advantage in serving small-batch, high-SKU markets across Southeast Asia, Africa, CIS, and the Middle East.
- Margins held up, with a mix-shift tailwind: EBITDA margin improved 50 bps YoY to 11.7%, and management sees an upward trend as higher-margin trade generics and injectables grow their share of the mix.
- What to watch next quarter: The pace of injectable facility validation, any inorganic deal to accelerate exports, and whether trade generics can sustain its ~50% growth momentum.
Injectable Facility: The Next Growth Cycle
- Timeline: Mechanical completion is expected by end of Q2 FY24, followed by 4–6 months of media fill and validation work before the first commercial batches can be shipped within FY24.
- Revenue contribution: Management expects the facility to start contributing to the P&L in FY24, but the major revenue impact will only materialize from FY25 onward.
- Margin profile: The business is expected to deliver an 18–20% EBITDA margin at optimal capacity utilization, which management defines as 55–60%.
- Asset efficiency: An asset turn of 1.2 to 1.3 is considered achievable, with physical space on the second floor already reserved to increase capacity in a subsequent phase.
- Start-up losses: Management acknowledged that any new facility will incur a period of small operating losses and is working to tie up capacity to minimize that period.
- Strategic role: The facility will serve all three verticals (CDMO, trade generics & institutional, and exports) and is seen as a key enabler for accessing ROW export markets where local injectable manufacturing is scarce.
Hitesh Windlas: "Since the injectables are sterile products that are put into the body directly, there is a huge amount of qualification work that goes on after the injectable. This is called as media fill and validation. This can take anywhere from four to six months. If you are lucky and everything happens in the first shot, it can be four months or if it is outer side, I would say six months."
Trade Generics: The Standout Performer
- Growth engine: Trade generics revenue grew 49% YoY in FY23 and 50% YoY in Q4 FY23, driven by the umbrella brand "Windlas Generics" and a unique distribution model.
- Distribution model: The company works directly with 600–700 stockists across India, enabled by a proprietary IT system that eliminates large intermediaries and improves control.
- Trajectory: Management expects to likely exceed the original target of tripling the trade generics business from the FY21 base if the current ~50% growth momentum is maintained.
- Profitability preference: Trade generics and exports are explicitly preferred by management as growth verticals because they offer better profitability and greater control compared to the CDMO business.
Hitesh Windlas: "We are working with almost 600-700 stockists directly across India. And we are able to do it because of the way we have built our IT system."
CDMO: The Steady Anchor
- Growth profile: CDMO revenue grew 5% YoY in FY23 and 14% YoY in Q4 FY23, supported by IPM volume recovery, new product launches, and increased DCGI permissions.
- Customer retention: In the company's 21-year history in CDMO, it has never lost a customer, though it has declined business that did not meet its ability to support the client.
- Client concentration: The top 10 customer percentage has declined below 50% due to a conscious effort to increase the customer base and revenue from new additions over the last few years.
- Capacity: The current oral solids facility can support up to approximately ₹600 crores in revenue, with no major capex planned for FY24, though expansion readiness may be needed by end of FY24.
Hitesh Windlas: "In the last 21 years history of the company in CDMO, we might have said no to a customer because it doesn't work for us, it doesn't meet our ability to support them. But, we have never lost a customer."
Exports: A Back-Ended Bet on ROW
- Current pain: Exports revenue declined 5% YoY in FY23 and 26% YoY in Q4 FY23, partly because a customer in Myanmar could not renew an import permit and some sales to Sri Lanka were stopped during a foreign currency crisis.
- Structural advantage: Management sees a natural CMO advantage in ROW markets (Southeast Asia, Africa, CIS, Middle East) because these markets require a very large variety of SKUs in small batch sizes, a profile that fits Windlas's existing manufacturing capabilities.
- Long gestation: Export growth is described as "back-ended" because the regulatory approval process takes approximately 1.5–2 years per product, meaning top-line impact from new dossier filings materializes with a significant lag.
- Market mix shift: Currently almost 100% of exports are to semi-regulated markets; the South Africa launch will add an SRA-type market, and the company is evaluating projects for the EU, though management declined to give a future ratio.
- Inorganic acceleration: The company is actively looking at inorganic opportunities to accelerate export growth because building internally takes a long time.
Hitesh Windlas: "The ROW space is a different space. And in the rest of the world, which between Southeast Asia, Africa, CIS, Middle East and so on, this space does not have very large batch sizes. And the number of SKUs required to serve a country with small batch sizes is very high. So, it has a natural advantage for a CMO player like us, which are used to manufacturing a very large variety of SKUs." [9–10]
Margins & Capital Allocation
- Margin trajectory: FY23 gross margins improved 160 bps YoY to 36.6%, and EBITDA margins improved 50 bps YoY to 11.7%, driven by operational excellence and strict cost management.
- Q4 expense uptick: Higher other expenses in Q4 FY23 were attributed to increased R&D, power & fuel, selling & distribution (linked to a high-sales quarter), and production/lab testing expenses, which management noted are not evenly distributed across quarters.
- Sustainability: Management stated that current EBITDA and material margins are sustainable, with an upward trend possible as the mix shifts toward higher-margin trade generics and exports, and as injectables contribute.
- Balance sheet strength: The company generated ₹61 crores in net cash flow from operations, completed a ₹25 crores buyback, paid a ₹7.6 crores dividend, fully utilized IPO proceeds of ₹165 crores on the injectable facility, and still maintained ₹138 crores in liquidity.
- Inorganic appetite: The company is evaluating several opportunities and is being very selective, with no restriction on deal size given its solid liquidity position; API is explicitly ruled out as a target space.
Komal Gupta: "In case we are able to catch up through trade generics and export verticals for the overall number that we are talking about for four years, we would be happier in that sense because they are better profitability and better control verticals for us."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable facility mechanical completion | Construction complete, ready for qualification | End of Q2 FY24 |
| Injectable facility first commercial batches | Post media fill and validation (4–6 months) | Within FY24 |
| Injectable facility major revenue contribution | Material top-line impact begins | FY25 onward |
| Injectable facility EBITDA margin | 18–20% at optimal utilization (55–60%) | At optimal capacity |
| Long-term segment targets (from FY21 base) | Double CDMO, triple trade generics, quadruple exports | ~4 years from current (delayed ~1 year from original 5-year target) |
| Oral solids capacity ceiling | Current facility supports up to ~₹600 crores revenue; expansion readiness may be needed | No major capex in FY24; possible expansion readiness by end of FY24 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Consolidated revenue | ₹140.7 crores |
| Consolidated EBITDA | ₹16.4 crores |
| Consolidated PAT | ₹11.4 crores |
| Gross margin | 36.8%, up 191 bps YoY |
| EBITDA margin | 11.7%, up 40 bps YoY |
| CDMO vertical revenue | ₹110.4 crores, up 14% YoY; 78% of consolidated revenue |
| Trade generics and institutional vertical revenue | ₹22 crores, up 50% YoY; 16% of consolidated revenue |
| Exports vertical revenue | ₹7 crores, down 26% YoY; 5% of consolidated revenue |
| FY23 consolidated revenue | ₹513.1 crores, up 10% YoY |
| FY23 consolidated EBITDA | ₹60.2 crores, up 15% YoY |
| FY23 consolidated PAT | ₹42.6 crores, up 12% YoY |
| FY23 gross margin | 36.6%, up 160 bps YoY |
| FY23 EBITDA margin | 11.7%, up 50 bps YoY |
| Net cash flow from operations (FY23) | ₹61 crores |
| Liquidity position (end of FY23) | ₹138 crores |
| Top 10 customer concentration | Below 50% of total revenue |
| CDMO market share | ~1% (per DRHP-era study) |
| Injectable facility investment | ~₹50 crores; expected asset turnover ~1.3x, targeting ₹70–₹80 crores revenue |
| Oral solids facility capacity | ~₹600 crores revenue supportable |
| Trade generics long-term growth target | Triple from FY21 base, on track to potentially exceed |
| CDMO long-term growth target | Double from FY21 base |
| Exports long-term growth target | Quadruple from FY21 base |